Cumberland Pharmaceuticals Inc. (CPIX) Plans Rolling NDA for Ifetroban in DMD Cardiomyopathy

Cumberland Pharmaceuticals (CPIX) plans to submit a rolling NDA for ifetroban to treat cardiomyopathy in Duchenne muscular dystrophy, using Phase 2 trial data and natural history comparators as support. The company aims for FDA approval following positive Phase 2 results and meetings with the FDA.

Original reporting
Published Oct 26, 2026, 8:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 26, 2026, 8:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Cumberland Pharmaceuticals Inc. (CPIX) Plans Rolling NDA for Ifetroban in DMD Cardiomyopathy — source image
Decision brief

The 30-second read

$CPIXBullishHigh
01

Why it matters

The rolling NDA filing is a fresh regulatory step that could materially affect the stock price depending on FDA feedback.

02

Market read

First‑report regulatory filing for a rare‑disease therapy; likely to move the stock.

03

What to watch

Potential competition from other DMD cardiomyopathy therapies and the company's cash runway.

Relevance 8/10Novelty 8/10Timing: upcoming NDA filing period

Background

Cumberland Pharmaceuticals is a Nasdaq‑listed biotech focused on rare‑disease treatments. The company has completed Phase 2 data for ifetroban in DMD cardiomyopathy.

Company-level read

Ticker impact

$CPIXBullishHigh confidence
Context

Cumberland Pharmaceuticals announced it will file a rolling NDA for ifetroban to treat cardiomyopathy in Duchenne muscular dystrophy, using Phase 2 data and natural‑history comparators.

Expected impact

potential upside as market prices in a successful NDA acceptance

Evidence & confidence

Regulatory filing is a material catalyst for a biotech; the company is small, so the news is likely to move the share price significantly.

Market effects

May boost sentiment for rare‑disease biotech stocks awaiting FDA decisions.

Limited to US biotech sector; no broader regional effect.

Modest global relevance, primarily for investors tracking rare‑disease therapeutics.

Counterpoint

If the FDA deems the natural‑history comparators insufficient, the NDA could be rejected, causing a sharp sell‑off.

Key entities

  • Cumberland Pharmaceuticals Inc.

    Biotech developer of ifetroban for DMD cardiomyopathy.

Related articles

$CPIXMedAI 8/10

Cumberland Pharmaceuticals Q3 Earnings Call Highlights

Cumberland Pharmaceuticals (CPIX) reported Q3 earnings, including a $108M net funding estimate from a transaction, a $1.50 special dividend, and share repurchase plans. The company projects cash to fund operations for over five years. Cumberland is preparing a new drug application for ifetroban to treat Duchenne muscular dystrophy, with FDA rolling review granted. The company also discussed other clinical programs and retained majority ownership of Cumberland Emerging Technologies.

$CPIXHighAI 8/10

CUMBERLAND PHARMACEUTICALS REPORTS Q3 2026 FINANCIAL RESULTS & COMPANY UPDATE

CUMBERLAND PHARMACEUTICALS INC (CPIX) filed an SEC Form 8-K — Results of Operations and Financial Condition. CUMBERLAND PHARMACEUTICALS REPORTS Q3 2026 FINANCIAL RESULTS & COMPANY UPDATE $100 million Strategic Transaction Closed Plans to Submit New Drug Application for Ifetroban in DMD Top-Line Results Announced for Systemic Sclerosis Trial NASHVILLE, Tenn. (Nov. 10, 2026) – Cumberland

$CPIXMedAI 8/10

CUMBERLAND PHARMACEUTICALS REPORTS Q3 2026 FINANCIAL RESULTS & COMPANY UPDATE

Cumberland Pharmaceuticals (CPIX) reported Q3 2026 results, highlighting a $100M strategic transaction and plans to submit an NDA for ifetroban to treat DMD-related cardiomyopathy. The company also announced positive top-line results from a systemic sclerosis trial. Cumberland's net income was $77.8M, with $80.6M in cash reserves. The company is focusing on developing new therapies for rare diseases.

$CPIXMedAI 8/10

Cumberland Pharmaceuticals Begins Rolling FDA NDA for Dyscorban in Duchenne Cardiomyopathy

Cumberland Pharmaceuticals (CPIX) has begun a rolling FDA NDA submission for Dyscorban to treat Duchenne cardiomyopathy. The FDA previously requested additional data, which the company plans to provide. Cumberland reported positive safety data from clinical studies and holds regulatory designations for the program. The company expects its balance sheet to fund development and NDA submission.